ماذا تفعل عندما لا يحقق العلاج الكيميائي من الخط الأول النتائج المرجوة في ورم الغدة الزعترية المتقدم غير القابل للاستئصال أو النقيلي (مرحلة ماساوكا-كوغا IVB)

References

DOI: 10.1093/annonc/mdv277

• Chemotherapy should be offered as single modality treatment in advanced, non-resectable, non-irradiable or metastatic (stage IVB) thymic epithelial tumours.
• Preferred regimens for second-line treatment include carboplatin plus paclitaxel, and platin plus etoposide [III, B]; capecitabine plus gemcitabine is an option (Table 6) [III, B].
• The re-administration of a previously effective regimen should be considered [IV, B], especially in case of previous response, late occurring recurrence and, for anthracyclines, a patient in a good medical condition who has not received cumulative doses precluding the safe delivery of at least three additional cycles.
• Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 criteria should be used to assess response to chemotherapy [V, A].